Abliva Q3’20: Energizing Interactions

Research Note

2020-11-23

07:20

Redeye believes the key takeaway from the recent quarter is the positive momentum in clinical and regulatory development for lead candidate KL1333. Abliva has also initiated preliminary discussions with a US clinical trial regarding a possible collaboration for non-core asset NeuroSTAT.

NE

Niklas Elmhammer

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.